Table 2.

EASE Trial Exclusion Criteria

Pulmonary Function	Change in FEV1 > 20% between pre-and post-bronchodilator measurements or >200 mL if the subject's post-bronchodilator FEV1 < 1 liter
	Clinically significant bronchiectasis
	Three or more respiratory infections requiring hospitalization in the last 12 months
	Respiratory infection <30 days prior to randomization
	Presence of segmental atelectasis, lobar consolidation, significant or unstable pulmonary infiltrate or pneumothorax confirmed on x-ray
	DLco <15% of predicted
Arterial blood gas analysis	Values on room air, pH <7.35 with a PaCO2 > 50 mmHg or PaCO2 > 60 mmHg regardless of pH
Physical	BMI >31.1 for males and >32.3 for females
	Unplanned weight loss >10% usual weight in 90 days prior to randomization
General Medical	Uncontrolled hypertension (systolic >200 mmHg or diastolic >110 mmHg)
	Stroke within last 12 months
	Suspicion or history of pulmonary hypertension, defined by either of the following: Abnormal Radionuclide Ventriculogram/Echocardiogram showing Right Ventricular Ejection Fraction <30%; or evidence of right ventricular dilatation; or evidence of hypokinesia; or RVSP >45 mmHg
	Myocardial infarction within 6 months
	Type 1 diabetes
	Current diagnosis of renal failure
	Lung cancer or pulmonary nodule requiring surgery
	Ventilator dependence
	Previous lung volume reduction surgery or lobectomy
	Known hypersensitivity to aspirin, paclitaxel or stainless steel